Products & Pipeline

We are developing and commercializing novel Digital Therapeutics for a variety of indications including smoking cessation, major depressive disorder, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity.

CT-100: Click Neurobehavioral Intervention (CNI) Platform

Product
Indication
Phase 1
Research
Phase 2
Design+PoDC
Phase 3
Pivotal Trial
Regulatory
Launch
Phase

CT-101
Clickotine

Smoking Cessation

Launch

CT-152

Major Depressive
Disorder

Phase 3

CT-141
Clickadian

Insomnia

Phase 2

CT-111
Clickheart

Acute Coronary
Syndrome

Phase 2

CT-155

Schizophrenia

Phase 1

CT-132

Migraine

Phase 1

CT-161

Overactive Bladder

Phase 1

CT-131

Chronic Lower
Back Pain

Phase 1

CT-181

Obesity

Phase 1

Clickotine

CT-101

An all in one, comprehensive digital smoking cessation program

learn more

Major Depressive Disorder

CT-152

Click is researching multiple cognitive exercises for the treatment of MDD.

Clickadian

CT-141

Clickadian is under development as a clinically-validated fully digital program for insomnia

learn more

Clickheart

CT-111

Clickheart is under development as a clinically-validated digital program for acute coronary syndrome

learn more

Schizophrenia

CT-155

Confidential

Migraine

CT-132

CT-132 is under development as a clinically-validated digital program for migraine

learn more

Overactive Bladder

CT-161

CT-161 is under development as a clinically-validated digital program for overactive bladder

learn more

Obesity

CT-181

Confidential

Additional Products in Research & Development

CT-131
Chronic Lower
Back Pain
Atopic
Dermatitis
Chronic Obstructive
Pulmonary Disease
Oncology
Osteoarthritis
Chronic Kidney Disease
Products in development are investigational Digital Therapeutics not for sale. FDA has not yet evaluated the safety or effectiveness of these products.